Latest & greatest articles for memantine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on memantine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on memantine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for memantine

1. Memantine

Memantine Top results for memantine - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for memantine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

4. Efficacy of memantine in the treatment of fibromyalgia: A double-blind, randomised, controlled trial with 6-month follow-up

Efficacy of memantine in the treatment of fibromyalgia: A double-blind, randomised, controlled trial with 6-month follow-up 25218600 2014 12 01 2015 07 15 2015 11 19 1872-6623 155 12 2014 Dec Pain Pain Efficacy of memantine in the treatment of fibromyalgia: A double-blind, randomised, controlled trial with 6-month follow-up. 2517-25 10.1016/j.pain.2014.09.004 S0304-3959(14)00424-2 Fibromyalgia (FM) is a prevalent and disabling chronic disease. Recent studies have found elevated levels (...) of glutamate in several brain regions, leading to hypotheses about the usefulness of glutamate-blocking drugs such as memantine in the treatment of FM. The aim of this study was to evaluate the efficacy of memantine in the treatment of pain and other clinical variables (global function, clinical impression, depression, anxiety, quality of life) in FM patients. A double-blind, parallel randomised controlled trial was developed. A total of 63 patients diagnosed with FM were recruited from primary health care

EvidenceUpdates2014

5. Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules

Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules U.S. Department of Health and Human Services Search FDA Submit search Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules Company: Forest Laboratories, Inc. Application No.: 206439 Approval Date: 12/23/2014

FDA - Drug Approval Package2014

6. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.

Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. 24381967 2014 01 01 2014 01 13 2017 02 20 1538-3598 311 1 2014 Jan 01 JAMA JAMA Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. 33-44 10.1001/jama.2013.282834 Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited (...) in mild to moderate AD. To determine if vitamin E (alpha tocopherol), memantine, or both slow progression of mild to moderate AD in patients taking an acetylcholinesterase inhibitor. Double-blind, placebo-controlled, parallel-group, randomized clinical trial involving 613 patients with mild to moderate AD initiated in August 2007 and concluded in September 2012 at 14 Veterans Affairs medical centers. Participants received either 2000 IU/d of alpha tocopherol (n = 152), 20 mg/d of memantine (n = 155

JAMA2014 Full Text: Link to full Text with Trip Pro

7. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.

Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. IMPORTANCE: Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD. OBJECTIVE: To determine if vitamin E (alpha tocopherol), memantine, or both slow progression of mild to moderate AD in patients taking an acetylcholinesterase inhibitor. DESIGN, SETTING (...) , AND PARTICIPANTS: Double-blind, placebo-controlled, parallel-group, randomized clinical trial involving 613 patients with mild to moderate AD initiated in August 2007 and concluded in September 2012 at 14 Veterans Affairs medical centers. INTERVENTIONS: Participants received either 2000 IU/d of alpha tocopherol (n = 152), 20 mg/d of memantine (n = 155), the combination (n = 154), or placebo (n = 152). MAIN OUTCOMES AND MEASURES: Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL

JAMA2014

8. Randomised controlled trial: Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine

Randomised controlled trial: Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine | Evidence-Based Medicine This site uses cookies. By continuing to browse the site (...) -to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine Article Text Therapeutics Randomised controlled trial Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine Pierre N Tariot Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Howard R , McShane R , Lindesay J , et al

Evidence-Based Medicine (Requires free registration)2013

17. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease.

Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. ACP Journal Club. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography (...) Citation manager Format Create File 1 selected item: 22711111 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Jun 19;156(12):JC6-10. doi: 10.7326/0003-4819-156-12-201206190-02010. ACP Journal Club. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. 1 . 1 St. Vincent's Health Network

Annals of Internal Medicine2012

19. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer?s disease (review of TA111): a systematic review and economic model

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer?s disease (review of TA111): a systematic review and economic model The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA111): a systematic review and economic model Journals Library An error has occurred in processing the XML document An error occurred retrieving content

NIHR HTA programme2012

20. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease

Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease Lachaine J, Beauchemin C, Legault M, Bineau S Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of adding memantine to the usual cholinesterase inhibitor treatment for patients with Alzheimer's disease. The authors concluded that the addition of memantine was cost-effective, compared with a cholinesterase inhibitor alone. The methods were

NHS Economic Evaluation Database.2012